EWTX vs NRP Comparison

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.